Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Single Arm Phase 2 Study of Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

NCT07471841 is registered in ClinicalTrials.gov with Timothy Pardee as lead sponsor.

NCT NCT07471841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07471841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Single Arm Phase 2 Study of Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Lead sponsor
Timothy Pardee
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
June 30, 2029
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idh1 mutation, relapsed / refractory aml